Table 2 Outcomes according to genetic subsets within the 2022 ELN.
Category | N | 1-year OS (%) | 2-year OS (%) | 3-year OS (%) | P value |
|---|---|---|---|---|---|
Favorable | |||||
NPM1mut, FLT3-ITD WT | 99 | 86.9 | 75.1 | 66.4 | 0.741 |
CEBPA-bZIP | 9 | 100.0 | 75.0 | – | |
inv(16) | 25 | 91.8 | 68.5 | 68.5 | |
t(8;21) | 17 | 81.4 | 61.0 | 61.0 | |
Intermediate | |||||
NPM1mut, FLT3-ITD mut | 45 | 74.7 | 47.9 | 47.9 | 0.201 |
NPM1 WT, FLT3-ITD mut | 11 | 74.1 | 74.1 | 74.1 | |
Other abnormalities | 44 | 88.6 | 72.7 | 72.7 | |
t(9;11) | 1 | – | – | – | |
Adverse | |||||
inv(3) | 10 | 15.6 | – | – | 0.002 |
(−5, −7, −17) | 35 | 56.8 | 34.4 | 23.0 | |
Complex karyotype and TP53 | 28 | 22.4 | 22.4 | – | |
Mutated TP53 | 5 | 45.0 | – | – | |
Complex karyotype | 27 | 57.7 | 25.6 | 25.6 | |
MDS-mutated genes | 145 | 59.5 | 38.2 | 38.2 | |
t(X;11) | 12 | 54.1 | 27.0 | – | |
t(6;9) | 5 | 100.0 | – | – | |
t(9;22) | 3 | – | – | – | |
